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1.1. Heart failure
Heart failure (HF) affects over 15 million people in Europe and
continues to increase, representing a major cause of hospitalization
and death [1]. HF is a condition that it is characterized and clinically
deﬁned by the inability of the heart to sufﬁciently supply normal
blood perfusion to organs and tissues as the end-point of several
physiological, genetic and environmental abnormalities. Coronary
heart disease accounts for ~70% of total clinical HF manifestations
[2]. Other main causes of HF are hypertension (~10%), cardiomyopa-
thies (~10%) and factors such as drug abuse, toxins and endocrine ab-
normalities (~10%) [1]. About half of the patients show near normal
contractile function and often hypertrophied heart (HF with pre-
served ejection fraction; HFpEF) with abnormal diastolic function,
which contrasts with the other half that present contractile dysfunc-
tion and a dilated heart (HF with reduced ejection fraction, HFrEF)
and impaired diastolic function [1,3].
1.2. Cardiac remodeling and contractile dysfunction
During each heart beat cardiac muscle cells (cardiomyocytes)
undergo changes in length and load. Diastole reﬂects the ability of the
heart muscle to relax and ﬁll with blood (preload). During the diastolic
phase, cardiomyocytes are elongated or stretched. During systole, con-
traction and ejection of blood is forced against the arterial resistance/
pressure (afterload) as a result of shortening of cardiomyocytes.
Sustained wall stress as occurs during pathological conditions such as
volume- and/or pressure-overload, ultimately reshapes cardiomyocytes
and the extracellular matrix (ECM) resulting in remodeling of the
wall geometry of the heart [4]. Eccentric remodeling of the heart is
associated with replication of sarcomeres in series and lengthening
of cardiomyocytes in order to accommodate a large increase in end-
diastolic volume (EDV; volume-overload) and maintain LVEF [4–6].
The cellular alterations decrease wall thickness and dilate the heart,
and eventually impair systolic function and reduce LVEF [4,5]. Concen-
tric remodeling of the heart is associated with replication of sarcomeres
in parallel and cardiomyocyte thickening, and is the direct result of
sustained pressure increase [6]. Concentric remodeling is associated
with incomplete LV relaxation and increased ﬁlling pressures, i.e.
increased LV end-diastolic pressure [4,5].
Cytoskeletal changes are both a cause and consequence of
contractile dysfunction and cardiac remodeling in HF patients. In
this review we will discuss the major changes in function andstructure of cytoskeletal components of cardiomyocytes which
occur during HF.
2. The ultrastructure of cardiac muscle
2.1. Contractile and cytoskeletal components
Cardiac muscle ﬁbers are composed of myoﬁbrils that contain
the contractile components of striated muscle, responsible for the
conversion of chemical energy into mechanical energy, in order to
perform work and generate force. Running parallel along the axis
of the cell, myoﬁbrils are deﬁned by a homogeneous succession of
transverse stripes, containing repeating individual units called sar-
comeres (Fig. 1, upper image). The sarcomeres can be subdivided
in two main components based on their speciﬁc characteristics:
1) the contractile proteins that govern muscle contraction and relax-
ation and 2) the structural scaffolding or cytoskeletal proteins. Myo-
ﬁlament contraction is governed by the thin actin and thick myosin
ﬁlament proteins that interact (cross-bridge) to generate force [7].
Force production and muscle shortening ensues as the collective
sum of all “activated” tension-generating cross-bridges. Regulation of
this interaction is dependent on the amount of available Ca2+ and
ATP aswell as the thin ﬁlament regulatory troponin–tropomyosin com-
plex that binds to actin and regulates cross-bridge interaction [8,9]. The
cytoskeleton forms the scaffold of cardiomyocytes as it regulates cell
shape, provides mechanical integrity and resistance, and stabilizes the
sarcomeric proteins. Importantly this structural framework mediates
biomechanical and biochemical signaling, both inwards and outwards
the cell, that thereby alters gene expression, post-translational mod-
ulation and protein synthesis, directly remodeling the myocardium
[10,11].
2.2. The role of contractile proteins in cardiac muscle function
Myoﬁlament activation and contractility depends on the interaction
between the thin actin and thick myosin ﬁlament. This interaction is
initiated upon electrical activation of cardiomyocytes and the resulting
increase in intracellular [Ca2+]. It has been suggested that the myoﬁla-
ments oscillate between three biochemical equilibrium transitions,
reﬂecting different interactions of actin andmyosin termed the blocked
(B-state), closed (C-state) and open (M-state) states of thin ﬁlament
regulation [8,9]. In the B-state Ca2+ is not bound to cardiac troponin C
(cTnC) and tropomyosin sterically blocks the myosin-binding sites on
actin. The B-state equilibrium is associated to a weakly bound state of
cross-bridges (i.e. weakly-bound cross-bridges). In the C-state Ca2+
Fig. 1. Schematic drawing of the anatomy of cardiac muscle. (Upper image) Illustration of a group of myoﬁbrils connected to the sarcolemma via the costameric network. Note the
striated pattern and separation of each individual sarcomere from one Z-disc to the other. Various sub-regions are observed that are based on their lighter or darker appearance
when viewed under the light microscope. (Bottom image) Illustration of an individual sarcomere. Note the formation of distinct band regions.
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and results in a ~25°movement of tropomyosin on the thin ﬁlament,
thereby exposing most of the myosin-binding sites on actin [9,12].
However in the C-state the myoﬁlament is not yet activated as
non-tension-generating cross-bridges are still weakly-bound to actin
(i.e. intermediate thin-ﬁlament activation). The third and last state,
the M-state, involves the strong binding of tension-generating cross-
bridges that induce an extra ~10° movement of tropomyosin on the
actin ﬁlament, resulting in myoﬁlament contraction and force develop-
ment [9,12].
Apart from beat-to-beat changes in intracellular [Ca2+], muscle
length and protein phosphorylation are important regulators of myo-
ﬁlament contractile properties.2.3. Length-dependent activation of the heart
The ability of the heart to adjust the force of its contraction (stroke
volume) in response to changes in ventricular ﬁlling (end-diastolic
volume) forms the basis of the Frank–Starling relation. Ventricular
ﬁlling sets the relation between sarcomere length and tension devel-
opment and determines the degree of muscle shortening, and thereby
regulates ventricular contraction and ejection [13,14]. At the ultra-
structural level (cardiomyocyte) an increase in muscle ﬁber length
as a result of increased ﬁlling during diastole, enhances the maximal
force generating capacity and Ca2+-sensitivity of myoﬁlaments, lead-
ing to increased force development during ventricular contraction
[13,14]. In other words there is a direct relation between sarcomere
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generated at a given concentration of Ca2+ as sarcomere length is
increased. The term ‘myoﬁlament length-dependent activation’ is used
to describe the length-dependent properties of the myoﬁlaments [13].
3. Sarcomeric dysfunction: from post-translational, to inherited
pathologies and Ca2+-mishandling
3.1. β-adrenergic receptor pathway and protein kinase
A-mediated phosphorylation
Intracellular Ca2+-levels are regulated by activation of the
β-adrenergic receptor pathway. Upon stimulation of the β-adrenergic
receptors by circulating catecholamines, cyclic AMP levels are elevated,
resulting in activation of the downstream kinase, protein kinase A
(PKA) [15]. PKA regulates positive inotropic, lusitropic and chronotropic
responses via phosphorylation of proteins involved in Ca2+-handling
and the myoﬁlament proteins cardiac troponin I (cTnI) [16,17], cardiac
myosin-binding protein C (cMyBP-C) [18,19] and titin [20]. Multiple
roles have been assigned to increased PKA-phosphorylation of myo-
ﬁlament proteins, such as reduced myoﬁlament Ca2+-sensitivity,
increased length-dependent activation and enhanced cross-bridge
cycling kinetics via phosphorylation of cTnI and cMyBP-C [21–25].
Defects in the response of myoﬁlaments to Ca2+, sarcomere
length and kinase-mediated phosphorylation have been described
in cardiac disease and may contribute to impaired cardiac function.
Defects in sarcomere contractile properties in HF will be brieﬂy
discussed (see Ref. [26]). A more thorough discussion will be given
on contractile dysfunction of sarcomeres in inherited hypertrophic
cardiomyopathy.
3.2. Sarcomere dysfunction in cardiac disease
Previous studies have shown that disease-related changes in pro-
tein phosphorylation via deﬁcits in the β-adrenergic receptor path-
way underlie changes in functional properties of the contractile
apparatus. Defects in PKA-mediated protein phosphorylation are
known to impair Ca2+-handling and contractile function of the myo-
ﬁlaments [27–29]. Low phosphorylation of cTnI [23,25], cMyBP-C
[21,28,30] and titin [20,31] have been associated with high myoﬁla-
ment Ca2+-sensitivity and high passive stiffness of cardiac myocytes
and may be important modiﬁers of disease progression. While post-
translational modiﬁcations, such as phosphorylation of contractile
proteins may be secondary in response to cardiac disease, mutations
in genes encoding contractile cardiac proteins have been identiﬁed
as direct cause of genetically inherited cardiomyopathies.
3.3. Mutations in sarcomere genes as a cause of
hypertrophic cardiomyopathy
Defective proteins as a result of gene mutations encoding sarco-
mere proteins directly impair regulation of muscle contraction and
lead to manifest hypertrophy [32]. Hypertrophic cardiomyopathy
(HCM) reﬂects the pathological phenotype associated with sarcomere
gene mutations and is the most common cause of sudden death in
young people [32,33]. Mutations in genes encoding the thick ﬁlament
proteins myosin heavy chain (MyHC) and cMyBP-C, and the thin ﬁla-
ment proteins account for ~98% of all HCM mutations reported thus
far [34]. Recent studies in human [35,36] and mice [37] demonstrated
early signs of cardiac dysfunction even before a hypertrophic pheno-
type is observed. In addition, acute cardiac arrest occurs in young
mutation carriers without evident cardiac remodeling [38]. Several
possibilities might account for the encompassing remodeling and
progression to HF including altered Ca2+-handling and impaired
β-adrenergic receptor signaling, which may be the direct or indirect
result of defective sarcomeric contractile proteins.3.4. Altered myoﬁlament Ca2+-handling in HCM
As indicated above, regulation of intracellular Ca2+ levels is cen-
tral to contraction and relaxation of cardiomyocytes. In this process,
the myoﬁlaments represent a major intracellular buffer for Ca2+
and any perturbation may provide a substrate for cardiac arrhythmias.
Both familial and non-familial forms of HF in human and animals are
associated with prolonged action potentials, sustained intracellular
Ca2+ accumulation and sudden cardiac death [27,39]. Alterations in
Ca2+-handling and subsequent perturbations in action potentials and
the occurrence of arrhythmias have been recently documented in a
transgenic HCM mouse model harboring mutations in the gene
(TNNT2) encoding the thin ﬁlament protein cardiac troponin T (cTnT).
Altered intracellular Ca2+-handling was linked to sensitization of myo-
ﬁlaments to Ca2+ [27]. Studies in transgenic animal models with thick
and thin ﬁlament mutations and in vitro studies using thin ﬁlament
mutant proteins indicate that elevated myoﬁlament Ca2+-sensitivity
is central in HCM development [32,37,40,41]. Accordingly, we recently
observed high myoﬁlament Ca2+-sensitivity in cardiac samples from
patients with manifest obstructive HCM [28]. Apart from the negative
effect on intracellular Ca2+-handling, myoﬁlament Ca2+-sensitization
has been associated with impaired cardiac relaxation. One of the early
clinical defects observed in humanmutation carriers without hypertro-
phy is impaired diastolic function [35,36]. In accordance, transgenic
mice with HCMmutations that show an increased Ca2+-sensitivity, ex-
hibit impairment of myocardial relaxation [37,42–44]. The combination
of human and animal data provides evidence that high myoﬁlament
Ca2+-sensitivity increases the intracellular Ca2+ buffering capacity of
myoﬁlaments, via mutation-induced mechanisms, resulting in cardiac
arrhythmias and compromising myocardial relaxation.
High myoﬁlament Ca2+-sensitivity was also observed in end-stage
HF patients and has been ascribed to phosphorylation deﬁcits, which
are most likely secondary to cardiac disease development [23]. Our re-
cent study in human HCM with mutations in the gene (MYBPC3)
encoding cMyBP-C showed that elevated Ca2+-sensitivity was asso-
ciated with reduced phosphorylation of the PKA-targets, cTnI and
cMyBP-C [28]. As PKA-mediated phosphorylation of cTnI decreases
myoﬁlament Ca2+-sensitivity, the high myoﬁlament Ca2+-sensitivity
in HCM may be explained by low phosphorylation of PKA target pro-
teins. Indeed, exogenous administration of PKA reduced myoﬁlament
Ca2+-sensitivity to control levels [28]. It remains to be investigated if
myoﬁlament Ca2+-sensitivity is high in HCM with mutations in the
other contractile proteins and whether the observed functional deﬁcits
are caused by the speciﬁc mutant contractile protein or a consequence
of secondary disease-related post-translation protein modiﬁcations.
3.5. Low phosphorylation of PKA targets in HCM
Low phosphorylation of PKA target proteins and high myoﬁlament
Ca2+-sensitivity, as found in human HCM [28,45,46], may be due
to impairments of the β-adrenergic signaling cascade. A blunted re-
sponse to isoproterenol, a β-adrenoreceptor agonist, has been re-
ported in transgenic mice harboring TPM1 and MYH7 mutations
[47,48]. Similar ﬁndings have been reported in mice expressing
the troponin T (cTnT) gene (TNNT2) mutation I79N, which showed
high myoﬁlament Ca2+-sensitivity and a limited inotropic response
to isoprenaline [29]. In the I79N muscle ﬁbers exogenous treatment
with PKA was sufﬁcient to decrease myoﬁlament Ca2+-sensitivity
to control levels [29]. These studies thus indicate that mutations in
genes encoding myoﬁlament contractile proteins potentially impair
the β-adrenergic signaling cascade of cardiomyocytes. Several pos-
sibilities (receptor down-regulation and desensitization) that are
known from HF development may underlie the impaired response
to β-adrenergic receptor stimulation in HCM [49]. Receptor down-
regulation is well documented in non-familial forms of HF [50,51]
and it has been reported in HCM patients [52]. However, reduced
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as both receptor density and afﬁnitywere unaltered in theMYH7R403Q
model compared to wild-type mice [47]. Instead, up-regulation and in-
creased activity of β-ARK1 (β-adrenergic receptor kinase 1) was found
in the latter study. β-ARK1 uncouples β-adrenergic receptors from its
downstream targets via phosphorylation and thereby reduces the re-
sponsiveness to catecholamines [53]. More recently, it has been demon-
strated that cTnT is an A-kinase anchoring protein (AKAP), as it tethers
PKA-regulatory subunits to the myoﬁlaments [54]. AKAPs tether inac-
tive PKA complexes at speciﬁc cellular locations, exposing the kinase
to isolated cAMP gradients, allowing activation of the PKA-catalytic
subunit [55]. It is tempting to speculate that mutation-induced struc-
tural alterations of the troponin complex alters the AKAP action of
cTnT to activate PKA upon an increase in free cAMP levels and there-
by inhibit PKA activity and its subsequent functional effects.
3.6. Impaired length-dependent activation in HCM
Both a depressed [56–58] or preserved [59–61] Frank–Starling
relation have been reported in HF studies in human and animals.
The study of HCM provides an important mechanistic asset to under-
stand how the sarcomere “senses” length alterations and translates
these length changes into myoﬁlament Ca2+-activation. It is known
that sarcomere length changes and myoﬁlament Ca2+-activation are
tightly modulated via the thin and thick ﬁlaments [13]. It follows
that genetically-induced abnormalities in these structural proteins
should directly impact the function and dynamics of the sarcomere.
A reduced Frank–Starling reserve has been observed in HCM pa-
tients and transgenic HCM mouse models with severe left ventricle
hypertrophy [62,63]. Studies on length-dependent activation of car-
diac muscle in human HCM are scarce. In human HCM with muta-
tions in the MYBPC3 gene, we recently reported impairment of
length-dependent activation which was restored after exogenous
administration with PKA [28]. Data on length-dependent activation
in transgenic mouse models harboring HCM mutations have been
conﬂicting and reported either reduced or preserved length-dependent
activation [21,64–66]. Findings in mousemodels are sometimes difﬁcult
to extrapolate to human due to differences in MyHC background:
the α-MyHC isoform is predominant in mouse ventricles, whereas
β-MyHC is the predominant form in the human adult ventricle.
A recent study by Ford and colleagues [66] in mice expressing the
TNNT2 R92L mutation in the physiological (mouse-like) α-MyHC
backgrounddemonstrated preserved length-dependent Ca2+-activation.
Interestingly, length-dependent activationwas impaired inmice harbor-
ing the R92L mutation in a human-like β-MyHC background [66]. These
studies emphasize the importance of sarcomere studies in cardiac sam-
ples from human HCM patients.
3.7. Filament geometry as a center of disease development
There is evidence to suggest that mutations disrupt protein–protein
interactions in the thin ﬁlament which result in abnormal thin ﬁlament
Ca2+-activation. The group of Geeves [67] emphasized the importance
of the troponin complex in stabilization of the B-state. In particular,
the N-terminal region of cTnT, which interacts with tropomyosin [68],
is able to maintain the thin ﬁlament in the B-state in complete absence
of other troponin subunits [69]. The terminal ends of cTnT and cTnI
which interact with tropomyosin and actin have been implicated in
stabilization of the B-state [70,71]. Murakami and colleagues [72]
showed that the C-terminal region (human residues 137–210) of TnI
that contains the second actin-binding site (mobile domain; residues
164–210), docks the troponin–tropomyosin complex into the outer
domain of actin at low cytoplasmic [Ca2+]. When intracellular [Ca2+]
rises both the ﬁrst actin-binding site (inhibitory region; residues
137–148) and the mobile domain of TnI are “pulled away” by TnC
and detach from actin, allowing tropomyosin movement on thethin ﬁlament and exposure of myosin-binding sites. Because of the
central roles of cTnT and cTnI in the transition from the B-state to
the C-state, it is possible that mutation-induced irregularities in pro-
tein–protein interactions translate into thin ﬁlament abnormalities.
Of particular interest, ~86% of cTnI HCM-causing mutations are
distributed in the C-terminal region [73]. Similarly, ~75% of cTnT
HCM-causing mutations are found in the TNT1 (residues 1–182) re-
gion and adjacent residues, a region that confers increased afﬁnity of
the troponin–tropomyosin interaction, which regulates tropomyosin
movement and cooperative Ca2+-activation of the thin ﬁlament
[74,75]. Indeed, disruption of the B-state has been suggested in
HCM-causing troponin mutations that were associated with increased
Ca2+-afﬁnity of reconstituted cardiac thin ﬁlaments [70,71]. Molecular
dynamics simulation of the thin ﬁlament, supports that HCM-causing
mutations in the TNNT2 gene reduce cTnT–tropomyosin interactions
and changes cooperative Ca2+-activation of the thin ﬁlament [76].
Disruption of protein–protein interactions and resulting abnormali-
ties, may be propagated via tropomyosin over a distance that spans
the entire thin ﬁlament [32,74,76].
Previousﬁndings suggest thatmyosin is not involved in the formation
of the ﬁrst two equilibrium states (B- and C-states), but is crucial to the
M-state (myosin-induced), as strong-binding of tension-generating
cross-bridges are required for thin ﬁlament activation and force
production [9,12]. Diverse β-MyHC HCM-causing mutations are
localized in the myosin S1 domain, responsible for actin-binding
[32,77]. Mouse models and in vitro studies of the β-MyHC R403Q
mutation demonstrated increased actin-sliding velocities, Ca2+-
sensitivity and ATPase activity [32], suggesting that the deleterious
effects of MYH7 mutations are mediated via perturbations of the
M-state. A recent study by Farman and colleagues [78] highlights
the essential role of myosin heads' orientation that precede thin
ﬁlament activation for proper lattice spacing and length-dependent
activation. Thus altered myosin head orientation as a result of muta-
tions may structurally and biochemically impair formation of the
M-state and affect length-dependent activation.
In summary, disruption of protein–protein interactions accompa-
nied by reduced troponin–tropomyosin afﬁnity may result in aberrant
ﬁlament geometry and underlie the pathogenesis of HCM. Impaired
myocardial relaxation precedes development of hypertrophy in HCM-
carriers [35–37], indicating that sarcomere mutations are the initial
trigger of the disease. Elevatedmyoﬁlament Ca2+-sensitivity and possi-
bly increased end-diastolic [Ca2+] [27,79], may reduce the capacity of
the human heart to fully relax and develop force, reducing the Frank–
Starling reserve which is observed in HCM pathology [29,62,63].
4. Myoﬁbrillar cytoskeleton
4.1. Cytoskeletal dynamics and structure
The sarcomeric cytoskeleton represents the main structural scaf-
fold of myocytes essential in the regulation of cell shape and mechan-
ical integrity, providing the uniform transmission of tension along
myoﬁbrils. Additionally, the cytoskeleton allows an integrative con-
nection to the extracellular milieu and thereby enables bidirectional
signaling, allowing the muscle to monitor and quickly respond to bio-
mechanical stress. For example, during conditions of sustained stress,
the cytoskeletal Z-disc senses biomechanical load signals upstream to
cardiomyocytes, such as mechanical overload, resulting in the activa-
tion of focal adhesion molecules at the sarcolemma. In turn these sig-
nals converge in the activation of downstream regulators, including
kinases, phosphatases, and transcriptional modulators, which acti-
vate fetal gene programs and remodel the heart [80,81].
The sarcomeric cytoskeleton can be divided in two main groups:
1) the “true” cytoskeleton proteins including actin, tubulin and desmin
[82] that structure and hold myoﬁbrils in place and 2) the myoﬁbril
cytoskeleton which integrates three major structural constituents:
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Zwischenscheibe; meaning “intermediate disc”, that transversely
delineates each side of the sarcomere, involved in the mechanical
linkage of thin ﬁlaments, uniform transmission of force and connec-
tion of myoﬁbrils to the sarcolemma and ECM; b) the elastic compo-
nent titin, which connects the Z-disc to the M-band, and runs along
the thick ﬁlament and parallel to the thin ﬁlament. Titin provides
sarcomere ﬂexibility and stability, and plays a major role both in
passive shortening and mechanical signaling of striated muscle; and
c) the M-band at the sarcomere center, from the GermanMittelscheibe
meaning “central disc”, involved in the organization and stabilization of
the thick ﬁlaments (Fig. 1, bottom image).
4.2. Muscle disorders
4.2.1. Myoﬁbrillar myopathies
Myoﬁbrillar myopathies (MFM) are a group of skeletal muscular
dystrophies histologically deﬁned by primary degeneration of myoﬁ-
brils, enhanced ﬁbrotic material, in addition to necrotic and regener-
ative ﬁbers (for extensive recent reviews on the topic see Refs.
[83,84]). The majority of MFM patients exhibit symptoms of slow
progressive muscle weakness that in some cases is accompanied by
development of cardiomyopathies [85]. Ultrastructural analysis re-
veals that the MFM pathology characteristically involves abnormali-
ties at the Z-disc. Myoﬁbril disintegration initiates at the Z-disc with
accumulation of myoﬁbrillar degraded products and unusual local de-
position of myoﬁbrillar proteins [83,85]. These depositions include
proteins such as desmin, αB-crystallin, γ-Filamin, myotilin, ZASP, FHL1
and others (discussed below) [85,86]. A small cohort of 80 patients
with MFM revealed that about 43% had a disease-associated muta-
tion [85] and with the growing improvements in genotyping and
high resolution ultrastructural techniques many more genes are
being recognized, such as recently the FHL1 (four-and-a-half LIM
domain) protein [86]. In accordance, mutation-induced MFM are sepa-
rately recognized dependent on the associated gene as desminopathy
(desmin),αB-crystallinopathy (αB-crystallin), ﬁlaminopathy (ﬁlamin),
myotilinopathy (myotilin), zaspopathy (ZASP) and FHL1opathy (FHL1)
[85,86].
4.2.2. Cardiomyopathies
Evidence indicates that at the time MFM affected-patients are diag-
nosed, some are accompanied by development of cardiomyopathies
(e.g. prolonged QT interval, intermittent atrial ﬁbrillation, conduction
block, abnormal depolarization) [87]. Mutations in desmin [88],
αB-crystallin [89], γ-ﬁlamin [90], ZASP [91], all have been associated
as causes of dilated cardiomyopathy (DCM) [92–94]. DCM is character-
ized by cardiac dilation and systolic dysfunction and is either acquired
(e.g. enteroviral infection; see below) or has a familial origin. It is esti-
mated that approximately 1:3000 individuals are affected worldwide,
accounting the familial form up to 20–50% of all DCM cases [95,96].
Opposite to HCM-disease causing mutations that are mostly restricted
to the contractile apparatus, DCM-causing mutations are identiﬁed at
the sarcomeric apparatus and the Z-disc [97]. DCM-causing mutations
have been shown to disrupt the cytoskeletal integrity and linkage to
the sarcomeric machinery, and interfere with force generation and
transmission, and energy production. A growing body of evidence im-
plicate mutations in the gene that encodes titin (TTN) as a common
cause of DCM (occurring in about 25% of idiopathic DCM cases)
[98–100]. Because titin spans the entire sarcomere structure connecting
the cytoskeleton and the sarcomeric apparatus (discussed further
below), mutation-induced alterations decrease its binding afﬁnity to
Z-disc elements and truncated forms of titin are found to lack important
binding sites for thick ﬁlament proteins [98–100]. Recently, titin muta-
tions have also been associated with arrhythmogenic right ventricular
cardiomyopathy (ARVC), thus supporting the central role of titin in
the heart [101]. Abnormal mechanical stretch-based responses due todiminish afﬁnity of cytoskeletal elements with accompanying weak
attachment of the cytoskeleton with the sarcolemma and the ECM are
all common disorders observed in DCM-disease [94,102,103].
4.3. Cytoskeletal proteins and cardiac disease
4.3.1. Actin
Initially termed as myosin B in 1941 [104], actin was thought to
represent a second form of myosin when extracted and puriﬁed
frommuscle. Myosin B as later called actomyosin, represented the po-
lymerized form of the two most abundant proteins found in striated
muscle, i.e. myosin and actin [105]. In striated muscle two isoforms
are predominantly expressed: α-skeletal actin (ACTA1; N95% present
in adult skeletal muscle) and α-cardiac actin (ACTC1; N80% in the
adult heart) that share near 99% homology [106]. Actin assembles
into a polymerized strand called the ﬁlamentous actin (F-actin) that
serves as a rigid cytoskeleton platform for the binding of troponin–
tropomyosin, the thin ﬁlament. Spanning the I-band, the opposing
fast growing (barbed) ends of actin ﬁlaments are “capped”, i.e. blocked,
and anchored by a protein called CapZ [107] to the Z-disc, in opposition
to the slow growing (pointed) ﬁlament ends that are capped in the
A-band by tropomodulin (Fig. 2) [108].
While striated muscle actins have a central role in thin ﬁlament
Ca2+-activation of force, several studies suggest that additional cellular
pools of actinmonomers exist, which are unrelated to actomyosin inter-
actions (and thus the contractile apparatus), and are part of the cellular
cytoskeleton, such as cytoplasmatic actin isoforms (γ-cytoplasmatic
actin, ACTG1; herein referred to as actin-based cytoskeleton) [109].
Also termed γ-smooth muscle actin, they compose the major isoactin
present in visceral organs [106]. Their in vitro separation has been how-
ever technically challenging in striated muscle, because over 99% of
total actin is α-actin [109,110]. With the development of high-afﬁnity
antibodies to recognize γ-cytoplasmic actin it was shown in chicken
skeletal muscle that they are absent from the thin ﬁlament apparatus,
but are internal constituents of the Z-disc, surround the mitochondria
and are found near the sarcolemma [109,110]. In addition, it was ob-
served that γ-cytoplasmic actin also co-localizes with subsarcolemmal
proteins, such as dystrophin, involved in ECM-membrane linkage
(i.e. the costameres, see below; Fig. 2) in both rabbit [111] and
mice [112,113] skeletal muscles.
Additionally, because actin interacts with a multitude of interacting
parterns, i.e. actin-binding proteins, which include capping proteins
involved in actin assembly/disassembly and anchoring proteins
such as α-actinin [114] and γ-ﬁlamin [115], it is not surprising
that mutation-induced actin abnormalities cause cardiomyopathies
[93,116,117]. The majority of actin-null mice do not survive (~60%)
or die within 2 weeks after birth [118], supporting the essential
cytoskeletal role of actin in striated muscle.
4.3.2. Tubulin
Together with actin, microtubules constitute the major component
of the cardiomyocyte cytoskeleton. Microtubules consist of αβ-tubulin
heterodimers, which assemble into microtubule polymers [119].
Together with intermediate ﬁlaments (e.g. desmin), microtubules
are involved in the assembly of myoﬁlaments during myogenesis
and adult myoﬁlament maintenance [10,82]. Polymerized tubulin
accounts for a small portion of total tubulin (~30%), while free
non-polymerized tubulin accounts for ~70% of cytosolic tubulin
[120,121]. Microtubules are organized around the nucleus and in
the longitudinal direction of the myoﬁbril space close to mitochon-
dria and along the plasma membrane, where they are suggested to
act as a dynamic transport system [122,123].
There is evidence to suggest that microtubules modulate
cardiomyocyte signaling andmay have an important role in disease
conditions, such as cardiac hypertrophy and HF where the heart
is subjected to sustained high loads [124]. Cooper and colleagues
Fig. 2. Schematic drawing of Z-disc and associated structures. Note the connection of the Z-disc to the sarcolemma and ECM (laminin).
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an important role during the transition from adaptive tomaladaptive
hypertrophy. The authors [125,126] showed that cardiac function
is inversely correlated with microtubule densiﬁcation and likely
potentiates and contributes to HF. Following pressure-overload and
wall stress increments, there was a substantial increase of tubulin
and microtubule network density in maladaptive hypertrophied
hearts. In contrast, tubulin and microtubule density were normal in
adaptive hypertrophy with normal contractile function and wall stress,
suggesting that microtubule density is associated to contractile defects.
Colchicine (which causes microtubule depolymerization) normalized
the contractile function in the dysfunctional heart, whereas treat-
ment of normal cardiomyocytes with taxol (to hyperpolymerize
the microtubules) caused the characteristic contractile dysfunction
of pressure-overload [125,126]. Increased tubulin production was
also observed in animal models with dilated hearts after supraventricu-
lar tachycardia [127] and monocrotaline-induced pressure-overload
(pulmonary hypertension) [128] associated with increased wall stress,
and in failing human myocardium caused by DCM [129]. Together these
ﬁndings indicate that mechanical forces caused by pressure-overload
and tachycardia initiate tubulin up-regulation andmicrotubule assembly,potentiating cardiac dysfunction and HF. In support, passive stretch
and contractile activity have been shown to increase tubulin content
in neonatal cardiomyocytes [130] and to result in cardiomyocyte
hypertrophy [131].
It has been suggested that the microtubule network density in-
creases to compensate for the abnormal increase inwall stress by im-
posing a viscous load [124,125]. A less compliant cardiac ventricle
associated with increased passive viscoelastic components may nor-
malize wall stress as it would restrict sarcomere shortening. The
Cooper hypothesis is nonetheless controversial. Although the authors
[125] provided evidence that microtubules play both a role in the
viscous (up to 4-fold increase) and elastic (about 2-fold) properties of
pressure-overload animals by the use of magnetic twisting cytometry,
their role is challenged by the involvement of titin. It has been demon-
strated that the contribution of titin within physiological levels, i.e. 1.8
to 2.2 μm, accounts for ~80% of total viscoelasticity (far greater than
collagen) and that the contribution of the microtubules is very modest
(about 10%) [132,133]. Additionally, actomyosin contributions to dia-
stolic stress has been recently shown to be about 30%, which would
form a greater viscoelastic element than the tubulin-based viscosity
[134]. As will be discussed below, the putative role of microtubules
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interact with sarcolemmal proteins, such as dystrophin [135,136]
(possibly involved in the stabilization of the microtubule network)
and integrins [131] (involved in stress or pressure-overload responses),
and thereby play a role in the response to stress stimuli induced by
pressure-overload (Fig. 3).
4.3.3. Desmin
Desmin is a muscle-speciﬁc cytoskeletal intermediate ﬁlament
that makes up the transverse network which maintains the myoﬁbril
apparatus in register and connects the nuclear membrane, Z-disc and
sarcolemma (Figs. 1 and 2) [123,137]. In cardiomyocytes, desmin is
transversely distributed along the myoﬁbril space, where it associates
with the outer portion of the Z-disc and with the intercalated disc
(cell–cell junction) [123]. In pressure-overload animal models, desmin
is longitudinally distributed between two displaced Z-discs, associated
with loss of the myoﬁbril register pattern and disorganization of the
sarcomeric structure [123]. This ﬁnding suggests that during pressure-Fig. 3. Schematic drawing of Z-disc andM-band components. Note the connection of M-band
ankyrin-B. It deserves to be mentioned that the intermolecular interactions between obscu
muscle and so, whether this complex is also structured in cardiac muscle remains to be deoverload hypertrophy, desmin forms a physical link with newly formed
sarcomeres, holding and maintaining myoﬁbrils in register, so that
force is normally propagated across myoﬁbrills [123]. Atrophy and
facial muscle weakness as well as cardiomyopathies are observed
in desminopathy patients, making it one of the major intermediate
ﬁlament disorders in human that is associated with mutations in
desmin [138]. Desminopathies are associated with cardiac arrhythmias
and restrictive HF [139], idiopathic DCM [88] and ARVC [140,141].
Desmin-null mice have severe disruption of sarcomere architecture,
associated with loss of lateral displacement and impaired myoﬁbril
anchorage to the sarcolemma and cell adhesion, indicative for the
essential role of desmin in maintenance of the sarcomere integrity
[142,143]. In failing human myocardium caused by DCM, where the
sarcomeric architecture is misaligned, desmin is up-regulated possibly
in an attempt to maintain the functional integrity of myoﬁbrils [129].
Mitochondrial and nuclear mislocalization and loss of organization,
with increased intercellular space, is also found inmouse lackingdesmin,
suggesting that it also holds subcellular organelles in place [144].and Z-disc components, possibly involving the microtubule network with obscurin and
rin, ankyrin-B, the microtubules and dystrophin have only been identiﬁed in skeletal
termined. For complete legend check Fig. 2.
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hypertrophy and chamber dilatation with systolic dysfunction and
HF [144].
Desmin-related myopathies have also been associated with
αB-crystallin [83]. αB-crystallin belongs to the family of small
heat-shock proteins that localize to the Z-disc (I-band) and interact
with desmin, possibly involved in intermediate ﬁlament assembly and
protection from stress [145,146]. Missense mutations (R120G) in the
gene encoding αB-crystallin (CRYAB) are linked with desminopathy
and are characterized bymyoﬁbrillar accumulation of dense desmin ﬁl-
aments [147]. Transgenic mice overexpressing wild-type αB-crystallin
do not show any signs of myofribrilar or cardiac myopathy which con-
trasts with mice expressing the missense mutation R120G that exhibit
desmin-related cardiomyopathy with myofribril misalignment and
100% lethality during initial adulthood [148]. As recently reviewed
[83,85], multipleαB-crystallin associated-mutations have been iden-
tiﬁed, which supports the categorization of αB-crystallin associated-
myopathies as a subgroup of MFM, i.e. αB-crystallinopathy. A newly-
identiﬁed αB-crystallin mutation (R157H) has been associated with
DCM in humans that is unrelated to αB-crystallinopathy [89]. It was
previously shown that αB-crystallin binds to the I-band region of titin
(N2B region, but not the PEVK; see below), which possibly confers
cardioprotection to titin upon stress [149,150]. The αB-crystallin
R157H mutant was found to have decreased afﬁnity with the cardi-
ac speciﬁc N2B domain of titin in familial DCM, suggesting that
αB-crystallins may be involved in the onset of DCM [89].
In summary, the cytoskeleton is a complex network of proteins in-
volved in assembly and maintenance of sarcomeres and myoﬁbrils.
F-actin assembles thin ﬁlament proteins and governs contraction
and relaxation, and provides the scaffold of all the cellular content
via an F-actin-based cytoskeleton. Interﬁlaments, such as desmin,
hold myoﬁbrils structural components in registration across the
ﬁbers, giving rise to the striated muscle pattern, and stabilize subcel-
lular organelles. The interﬁlament network is capable to physically
link newly formed sarcomeres and hold myoﬁbrils in register to
maintain the uniform transmission of force. Although the role of
the microtubule network remains unclear and less likely to have a
mechanical role during cardiac hypertrophy, it is likely that their
contribution is linked with sarcolemmal proteins during biomechan-
ical stress (discussed below).
As will be further discussed the sarcomeric machinery, in particular
the Z-disc, links external stimuli to the intracellular environment of
cardiomyocytes via interaction with membrane-associated proteins of
the costameric network.
4.4. The Z-disc
Not just a static complex that both provides the physical separa-
tion between each sarcomere and stabilizes the propagation of force
along and laterally to neighboring sarcomeres, the Z-disc is able to
monitor and sense biomechanical stress. This unique property confers
the myoﬁbrils the ability to quickly adapt to different load conditions.
The lateral connections of the Z-disc with the sarcolemma and ECM
allow bidirectional communication. Although a precise division of
all proteins at or near the Z-disc is extremely challenging, we make
a simpliﬁed subdivision taking into consideration their main func-
tions and locations. Three main groups can be classiﬁed in terms of:
1) formation of the structural scaffold of the Z-disc. This group in-
cludes structural proteins mainly located at the Z-disc, which directly
interact with actin andmay provide a link of the Z-disc to transmem-
brane proteins. These structural proteins include α-actinin, CapZ,
ﬁlamins, myotilin and members of the nebulin family; 2) transmem-
brane complexes that are adjacent to the Z-disc and interact with
actin and/or actin-binding proteins, thereby connecting the Z-disc
to the sarcolemma and ECM. These include the costameres, which
can be sub-divided into two major protein complexes that givephysical stability and regulate biomechanical signaling either from
the ECM into the Z-disc or vice versa, such as the dystrophin–
glycoprotein complex and the integrin–vinculin–talin complex [151];
and 3) Z-disc associated proteins involved in strengthening of the
cytoskeleton-sarcolemma grid via interaction with actin-binding pro-
teins and the costameres, involved in signaling. These associated pro-
teins include FATZ (ﬁlamin-, actinin-, and telethonin-binding protein
of the Z-disc) and PDZ-LIM and LIM-only proteins. A representative pic-
ture of some Z-disc components is presented in Fig. 2.
Countless components of the Z-disc have been extensively reviewed
in recent years and although the vast majority have been linked to
cardiac dysfunction and development of cardiomyopathies [11,152],
their thorough and detailed discussion is outside the scope of the
present review. Instead, the main constituents and their associations
will be presented below.
4.4.1. Z-disc structural scaffolding
4.4.1.1. α-actinin. Themain component of the Z-disc isα-actinin, which
accounts for ~20% of total Z-disc proteins [153]. In the human heart,
only one of the four isoforms (α-actinin-2; ACTN2) is expressed and
mutations in this gene have been associated with both HCM and DCM
[154–156]. Alpha-actinin cross-links and connects the ends of F-actin
[114,157] and provides the direct physical connection between the
actin cytoskeleton and transmembrane receptors, thereby maintaining
the integrity of the Z-disc structure. Aside from its physical role,
α-actinin governs the activity of diverse signaling pathways via direct
interactions with several binding partners. α-actinin is known to inter-
act with many Z-disc and membrane-associated proteins including
CapZ [107], myotilin [158], N-RAP [159], vinculin [160], integrins
[161], PDZ-LIM domain proteins [162–165], zyxin [166], titin [167]
and FATZ [168]. Given its multiple associating binding partners, it
suggests that α-actinin may play a determinant role in mediating
and integrating mechano-connections at the Z-disc, as indicated by
the diverse clinical presentations of α-actinin-associated diseases
[154–156].
4.4.1.2. CapZ. α-actinin strengthens the anchorage of F-actin to the
Z-disc via an actin capping protein, called CapZ [107]. CapZ binds to
the barbed ends of F-actin and blocks, i.e. “caps”, either actin depoly-
merization and polymerization (prevents either the loss or addition
of actin monomers) [107,169]. CapZ is arranged in a dimer association
of α- and β-subunit isoforms [170]. In cardiomyocytes, two β-subunit
isoforms are expressed with different cellular locations. β1-subunits
are primarily located at the Z-disc responsible for anchorage of F-actin,
whereas β2-isoforms are present in intercalated discs [171,172]. Over-
expression of β2-isoform in transgenic mice is associated with develop-
ment of HCM as a result of disruption of the sarcomeric architecture,
while β1-isoform over-expression results in altered morphology of the
intercalated disc [172]. In agreement, loss of function of β1-isoforms
may lead to a diminished number of attached thin ﬁlaments to the
Z-disc and consequent myoﬁbrillar disarray [172].
4.4.1.3. γ-Filamin. Filamins are a family of cytoskeletal actin-binding
proteins involved in the organization of actin ﬁlaments in bundle
networks. In humans, three different ﬁlamin isoforms exist, of which
γ-ﬁlamin (also known as ﬁlamin C or ﬁlamin-2) is the only isoform
expressed in striated muscle [115]. In cardiac muscle, ﬁlamin is located
both at the Z-disc and sarcolemma [173], where it interacts with a vari-
ety of transmembrane receptors including members of the costameric
network, such as the sarcoglycan complex [174] and the focal adhesion
β1-integrin [175]. γ-Filamin also interacts with other actin-binding
proteins including myotilin [176], N-RAP [159], and the multiprotein
complex FATZ [168]. Mutations in the gene enconding γ-ﬁlamin
(FLNC), i.e. ﬁlaminopathy, are characterized bymyoﬁbrilar disorganiza-
tion and abnormal accumulation/aggregation of myoﬁbrillar proteins
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exhibit progressive muscle weakness [177,178]. In addition, ﬁlamin
mutations have also been linked to DCM [90].
Together these studies highlight the dual role of ﬁlamin: it pro-
vides structure and stability to the Z-disc via its interaction with
actin and links membrane-related signaling via transmembrane pro-
teins. In addition, ﬁlamin plays a role in early embryonic events,
where it has been associated with early myotube formation [179].
4.4.1.4. Myotilin. Myotilin is a protein expressed in both cardiac and
skeletalmuscle that interacts at the Z-discwithα-actinin, and is present
along the sarcolemmal membrane [158]. It binds to F-actin and is able
to promote F-actin cross-linking, either alone or in association with
α-actinin, and thereby involved in Z-disc integrity [180]. In addition,
myotilin interacts with FATZ [175] and γ-ﬁlamin [176]. It has been
suggested that myotilin plays an important role in stabilization and an-
chorage of Z-disc elements, and possibly is required for proper Z-disc
organization. Mutations in the myotilin gene (MYOT) were ﬁrst
found by Hauser and colleagues [181] whom identiﬁed the disease-
causing mutation associated with limb-girdle muscular dystrophy
1A (LGMD1A) in patients. Mutations in myotilin are known causes
of muscular dystrophies, i.e. myotilinopathy, which are associated
to Z-disc abnormalities, as well as cardiomyopathies, thus supporting
its role in Z-disc stabilization and integrity [181,182]. In addition,
it has been recently demonstrated that myotilin interacts at the Z-disc
with ZASP/Cypher, amember of the enigma subfamily, ALP (α-actinin as-
sociated LIM protein), involved in Z-disc stability, and also binds titin at
the Z-disc [176,183,184]. Interestingly, Ca2+/calmodulin-dependent pro-
tein kinase (CaMKII) was shown to phosphorylate myotilin, which
appears to strengthen the binding of myotilin to ZASP/Cypher [183].
Myotilin-null mouse have structural preserved Z-discs with normal
sarcomeric and sarcolemmal integrity, and do not show morphological
abnormalities of neonatal and adult hearts [185]. This ﬁnding suggests
that myotilin either does not play a role in embryonic development
and basal maintenance of the heart or that other proteinsmay compen-
sate for its absence, such as the titin-interacting protein telethonin,
which was found to be upregulated [185].
4.4.1.5. The nebulin family members. The nebulin family of actin-binding
proteins comprises three proteins that are speciﬁc of striated muscle:
nebulin, nebulette and N-RAP (nebulin-related anchoring protein) and
two additional proteins with ubiquitous tissue expression: lasp-1 and
lasp-2 (LIM and SH3 protein-1 and -2, respectively) [186].
Nebulin is a giant actin-binding protein that makes up 3% of the
myoﬁbrillar content of skeletal muscles [187]. Because it spans the en-
tire thin ﬁlament with its C-terminal region anchored to the Z-disc
(Mw 600–800 kDa), nebulin has been regarded has a “protein-ruler”
of skeletal muscle thin ﬁlaments [187,188]. Nebulin-deﬁcient mice
have on average shorter thin ﬁlament lengths that are associated with
reduced force production [188,189]. Recent evidence, however, demon-
strates that nebulin is far from being just a strict length “ruler”. In accor-
dance, nebulin is suggested to be part of a multiprotein complex that
laterally links myoﬁbrils at the Z-disc and regulates its structure
(i.e. Z-disc width), essential for lateral transmission of force [190].
Additionally, there is evidence to support that nebulin regulates
muscle contraction via regulation of cross-bridge cycling kinetics
and Ca2+-sensitivity of force (for an extensive recent review on the
topic see reference [190]). Mutations in the nebulin gene are associ-
ated with nemaline myopathy (NM) [191], a non-progressive type of
neuromuscular disorder characterized at the ultrastructural level by
the presence of rod-like bodies (i.e. nemaline rods) with disrupted
sarcomeric structure andwidened Z-discs [192]. Clinically, the hallmark
of NM-patients is muscle weakness and it is estimated that approxi-
mately 1:50.000 individuals are affected worldwide making it the
most common non-dystrophic congenital myopathy [192]. Mutations
in several thin ﬁlaments genes including skeletal muscle ACTA1, TPM2and TPM3, and TNNT1 have been associated with NM, while mutations
in the nebulin gene (NEB) represent themost common cause of autoso-
mal recessive forms of NM [191].
Nebulette, the myoﬁbrilar homolog protein of skeletal nebulin, is a
small isoform (Mw 107 kDa) speciﬁc of cardiacmuscle that it is located
at the Z-disc [193,194]. In contrast to nebulin that spans the entire thin
ﬁlament of skeletal muscle, nebulette is predicted to only extend 25% of
the thin ﬁlament length from the Z-disc region [193,194]. Because
nebulette does not span the entire cardiac thin ﬁlament length, it is
unlikely to serve as a protein-ruler. However, over-expression of
nebulette's C-terminal linker region (anchored within the Z-disc) is
associated with loss of endogenous nebulette and a decrease in
thin ﬁlament length [195], which suggests that nebullete is involved
in a mechanism that speciﬁces and stabilizes thin ﬁlament lengths.
The central nebulin-like repeat domains of nebulin/nebulette inter-
act with several thin ﬁlament proteins including actin, troponin and
tropomyosin [196,197]. Nebulette is required to maintain tropomyosin
interaction with the thin ﬁlament [198], such that it increases the afﬁn-
ity of the troponin–tropomyosin assembly to F-actin, suggesting a pos-
sible role in the assembly and regulation of thin ﬁlament transitions.
In addition, the C-terminal linker region of nebulin/nebulette interacts
with interﬁlaments and Z-disc associated proteins, such as desmin
[199], α-actinin [193,200], CapZ [201], myopalladin [202], zyxin [203],
titin [201,204], ZASP and γ-ﬁlamin/ﬁlamin C [205]. Nebulette muta-
tions are associated with DCM in patients, and transgenic mice die
before birth or develop DCM with disrupted I-band and/or Z-disc
structure [206]. Down-regulation of contractile proteins including
cTnI, cTnT and tropomyosin was observed in some nebulette DCM-
causing mutations, in addition to down-regulation of α-actinin,
nebulette and desmin, and cleavage of γ-ﬁlamin/ﬁlamin C [206].
One can speculate that lack of (functional) nebulette would impair
thin ﬁlament length and reduce the amount of expressed cardiac
troponin subunits. Finally, nebulette has been demonstrated to be
present during early stages of cardiogenesis along F-actin, suggesting
a possible role during early formation of the cytoarchitecture of the sar-
comere [207]. Indeed, upon mechanical stretch in cardiomyoblasts,
nebulette's distribution shifts from a uniform perinuclear localization
to the whole cytosol along with F-actin, suggesting that nebulette may
function as amechano-sensor duringmyogenesis tomaintain the struc-
tural and functional integrity of cardiomyocytes [206].
N-RAP is a large actin-binding protein of the nebulin family
(Mw 196 kDa) that has been implicated in the assembly of myoﬁbrils
during myoﬁbrillogenesis in both cardiac and skeletal muscle [186,208].
In accordance, evidence indicates that N-RAP's early localization is in
Z-disc precursors where it shifts to the myotendinous junctions and in-
tercalated discs of matured skeletal and cardiac muscle, respectively
[186]. N-RAP also binds toα-actinin andﬁlamin, possibly assisting the as-
sembly of F-actin andpromoting the regulation of Z-disc assembly during
early stages of development [159,208]. Speciﬁc N-RAP protein knock-
down with RNA interference in cultured embryonic cardiomyocytes
demonstrated that N-RAP is required for α-actinin organization and
proper formation and assembly of myoﬁbrils [209].
The other two nebulin protein members, lasp-1 and lasp-2, com-
prise the smallest members of the nebulin family (Mws 37 kDa and
34 kDa, respectively), and have multiple tissue expression patterns
[186]. Lasp-1 is ubiquitously expressed in almost all tissues although
expression is relatively low in the heart and skeletal muscle [210]. Its
role in striated muscle is largely unknown. Lasp-2 is a splice-variant
of nebulette (also termed LIM-nebulette) that is present in muscle
and non-muscle tissue [203]. Opposite to lasp-1, lasp-2 has been re-
cently associated with early development of myoﬁbril structures of
chicken embryos and thus seems to play a role duringmyoﬁbrillogenesis
[211]. In accordance, lasp-2 is found in nascent Z-discs,where it interacts
with both actin and α-actinin, but also localizes at the focal adhesions
and intercalated discs of cultured cardiomyocytes [211]. According to
Zieseniss and colleagues [211] lasp-2 may promote the stabilization or
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of myofbrils to the sarcolemma at the focal adhesions or intercalated
disc areas.
Taken together these ﬁndings suggest that members of the nebulin
family may be involved in myoﬁbril assembly with maintenance of
the Z-disc structure and thin ﬁlaments maturation, myoﬁbrils attach-
ment to the sarcolemma, in addition to Ca2+-activation of the thin
ﬁlament.
4.4.2. Membrane-associated proteins, the costamere
Responsible for the physical communication between the Z-disc,
the sarcolemma and the ECM, the costameres surround the circum-
ference of cardiomyocytes (Figs. 1 and 2) [109,212]. Lateral transmis-
sion of force by the costamere is thought to maintain a homogenous
sarcomere length of contracting and resting cells, thereby withstand-
ing high forces and minimizing stress [213,214]. The stability exerted
by the costamere may in part be due to its direct interaction with
the ECM [215]. It is generally assumed that the biomechanical role
exerted by the costamere is bidirectional, as it either transmits signals
from the extracellular environment to the intracellular milieu and
vice versa [151,214]. The costamere is known to be involved in phys-
iological or pathological growth of cardiomyocytes as a result of me-
chanical loads [216,217].
The costamere can be subdivided in two main protein complexes,
the dystrophin–glycoprotein and the integrin–vinculin–talin complexes,
whichprovide physical stability and integrity to the costamere, and have
an important role in biomechanical signaling in response to stress
stimuli [151].
4.4.2.1. Dystrophin–glycoprotein complex. The dystrophin–glycoprotein
complex is responsible for providing the physical association between
the ECM and F-actin and includes subsarcolemmal proteins, such as
dystroglycan, dystrophin, sarcoglycans and sarcospan [151]. A complex
of dystroglycan proteins binds the basal lamina protein (laminin) of the
ECM to dystrophin, that via actin–dystrophin interactions anchors and
stabilizes the dystrophin–glycoprotein complex to the cytoskeleton
[111,113,218]. Mutations in dystrophin, known to cause either
Duchenne's or Becker's muscular dystrophy, are involved in the devel-
opment of DCM, and are associated with loss of sarcolemmal integrity
[219–221]. Additionally, mutations in an actin domain known to inter-
act with dystrophin have been found in DCM [93]. Not just conﬁned to
familial forms, DCMhas been shown to be acquired by enteroviral infec-
tion. Badorff and colleagues [222] demonstrated that the enterovirus
protease 2A cleaves dystrophin and contributes to an acquired form of
DCM. Additionally, it has been suggested that dystrophin links the
costamere to the cytoskeleton, possibly directly organizing and/or sta-
bilizing the microtubule network [135]. In a similar way, Randazzo
and colleagues [136] suggested that the microtubule network affects
the localization of dystrophin at the sarcolemma, under themodulation
of the giant protein obscurin (Fig. 3, discussed further below). Together
these ﬁndings support a linkage of microtubules with the costameric
network and the ability of the microtubules to respond to stress. More-
over, the stabilization of dystrophin–glycoprotein complex at themem-
brane is strengthened by sarcoglycans–sarcospan interactions [223].
Sarcoglycans are required for maintenance of the membrane integrity
[223] and mutations that reduce their expression, without affecting
the dystrophin–glycoprotein complex, cause muscular dystrophies
[224,225]. Of interest, an up-regulation of the γ-ﬁlamin/ﬁlamin-2
was observed in patients with mutations in both sarcoglycan and dys-
trophin [174]. It appears that γ-ﬁlamin/ﬁlamin C over-expression is
the required compensatory response to balance low expression of
sarcoglycan and dystrophin in order to maintain mechanical stress
resistance [174]. Altogether these ﬁndings support that disruption of
the dystrophin–glycoprotein complex is associated with a reduction of
the sarcolemma's stability and integrity, weakening the attachment
of the ECM to the cytoskeleton.4.4.2.2. Integrin–vinculin–talin complex. The second complex group of
transmembrane proteins comprises the integrin–vinculin–talin com-
plex that is responsible for bidirectional transduction of biomechani-
cal signals in response to stress or pressure-overload [226]. Vinculin
was the ﬁrst protein to be found at the costameres [212] and it is
involved in the mechanical linkage of the actin cytoskeleton to the
sarcolemma [160]. Talin is able to interact with F-actin, vinculin
and integrins, allowing the formation of a integrin–vinculin–talin
multicomplex [151,227–229]. It has been demonstrated that vinculin
and its isoform variants are responsible for normal mechanical stress
responses of the heart [230]. Transgenic heterozygous knock-out
mice with reduced protein levels of vinculin and its splice variant
metavinculin showed misalignment of α-actinin and abnormal
sarcomeric architecture accompanied by cardiac dysfunction and
increased mortality after pressure-overload [230]. Mutations in
metavinculin have been recently associated to DCM in humans and
result in disruption of the transmission of force at the intercalated
discs via abnormal actin ﬁlament organization leading to irregular
intercalated discs and sarcomere structure [231,232]. Together
these ﬁndings support the role of vinculin in the formation of a
multicomplex at the costamere, providing a stable connection of
the myoﬁbril to the sarcolemma, whereby cardiomyocytes are able
to respond to stress stimuli following pressure-overload.
Central to the integrin–vinculin–talin complex and mechano-
transduction of signals are integrins, regulators of cellular adhesion
and mechano-transduction. Integrins are the interface between the
intra- and the extracellular network, and are responsible for mediat-
ing bidirectional signaling [226]. Via their extracellular domain,
integrins bind to various ligands present in the ECM (e.g. ﬁbronectin,
vitronectin, collagen, laminin), and make a bridge to the actin cyto-
skeleton via talin and vinculin [151,233]. It has been suggested that
cardiac remodeling after myocardial infarction is initiated at the in-
tercalated disc of the damaged area via translocation of ECM and
integrin constituents [234]. Up-regulation of integrins is observed
during mechanical stress and as a result it has been suggested that
integrins govern central mechanical stress responses via strengthen-
ing of the cytoskeleton–matrix association [235,236]. Upon mechan-
ical overload, the stress response is propagated from the ECM to
integrins, promoting expression of fetal and growth genes leading
to hypertrophy [235,237,238]. In human failing myocardium caused
by DCM, vinculin is up-regulated (in combination with tubulin
and desmin) possibly via integrin–ECM interactions to maintain
the physical integrity of the cytoskeleton [239]. In addition, one can
hypothesize that integrins may associate with the microtubule
network. β1-integrin blockade suppressed polymerization of micro-
tubules and hypertrophy, in neonatal cardiomyocytes, mimicking
the effects of colchicine in the inhibition of the stretch-based response
[131]. This ﬁnding suggests a possible association between microtu-
bules and integrins, which together with dystrophin–microtubule in-
teractions, may represent a hot-spot of microtubules organization at
the costameres, allowing the cytoskeleton to remodel following me-
chanical stress.
4.4.3. Z-disc associated-proteins involved in structure and signaling
4.4.3.1. Myopalladin. Myopalladin (Mw 145 kDa) was identiﬁed by
Bang and colleagues [202] using a yeast two-hybrid approach when
searching for potential protein candidates involved in tethering of
nebulin/nebullete to the Z-disc. Because of its high homology to paladin,
a protein present in stress ﬁbers of non-muscle cells [240], the authors
named it myopalladin [202]. Together with myotilin, myopalladin
belongs to a family of cytoskeletal proteins that regulate actin organiza-
tion, Z-disc assembly and morphogenesis [241]. Myopalladin is a Z-disc
bindingprotein that is expressed in striatedmuscle,where it localizes to
the Z-disc, the I-band and the nucleus [202]. At the Z-disc, myopalladin
interacts with several proteins including α-actinin, titin and nebulin/
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structure, since over-expression of its N-terminal region leads to
Z-disc disrupture and sarcomere disassembly [202]. In addition, in
the I-bandmyopalladin interacts with cardiac ankyrin repeat protein
(CARP), which is involved in cardiogenesis [242], suggesting a puta-
tive link between the Z-disc and cardiac gene expression regulation
[202]. In agreement, myopalladin mutations are known to cause ei-
ther DCM or HCM in humans, which are associated with disturbed
myoﬁbrillogenesis and sarcomere/Z-disc assembly [243–245].
4.4.3.2. FATZ (ﬁlamin-, actinin-, and telethonin-binding protein of
the Z-disc). FATZ, the abbreviation for γ-ﬁlamin, α-actinin, telethonin-
binding protein of the Z-disc, is a sarcomeric protein family implicated
in the assembly and stabilization of the Z-disc in striated muscle [168].
Independently, two additional laboratories identiﬁed FATZ in a yeast
two-hybrid assay, although different terms were given: calsarcin
(for calcineurin-associated sarcomeric protein) [246] and myozenin
(a γ-Filamin and α-actinin interacting protein) [247].
The FATZ family is comprised of 3 members, FATZ-1 (calsarcin-2
and myozenin-1), FATZ-2 (calsarcin-1 and myozenin-2) and FATZ-3
(calsarcin-3 and myozenin-3), that interact with the Ca2+/calmodulin
protein phosphatase, calcineurin, tethering it to the Z-disc [168,248].
Calcineurin is a known Ca2+-activated phosphatase that is involved in
the expression of hypertrophic genes [249,250]. FATZ-1 and FATZ-2
are expressed during embryonic development of cardiac and skeletal
muscle. FATZ-1 is restricted to adult fast skeletal muscle, while FATZ-2
is mainly expressed in adult cardiac and slow skeletal muscle [246].
FATZ-3 is exclusively expressed in fast skeletal muscle [248]. In addi-
tion, FATZ members interact with several other proteins, including
ZASP/Cypher/Oracle [184,248] (members of the PDZ–LIM-protein
family), ALP [183], and myotilin [175], indicating a potential role as
structural scaffold. The role of FATZ and regulation of calcineurin
has been evaluated using transgenic mice lacking FATZ-2 [251]. In
FATZ-2-null mice calcineurin activity was up-regulated, suggesting
that functional FATZ-2 represses calcineurin activation. Mutations
in the FATZ-2 gene (MYOZ2) have been identiﬁed as a novel gene
for HCM [252]. However, after screening a large cohort of over 400
HCM patients no mutation was found which led the authors to con-
clude that MYOZ2 mutations are an uncommon cause of HCM [253].
Overall, studies in human and mice models suggest that FATZ-2
may have a modulating role in development of hypertrophy.
4.4.3.3. PDZ–LIM proteins. PDZ–LIM proteins are characterized by a
PDZ and one or more LIM domains, which via their interaction with
α-actinin constitute one of the biggest family members of Z-disc asso-
ciated proteins [162–165]. The term PDZ is the abbreviation for the
ﬁrst three identiﬁed PDZ proteins ‘postsynaptic density 95, discs
large, and zonula occludens-1’ and consist of protein domains that
play an active role in targeting and assembly of protein complexes
[254]. LIM domains are the acronym for the ﬁrst three identiﬁed
LIM-domains ‘LIN-11, Isl1m, and MEC-3’, which mediate protein–
protein interactions [255].
As recently reviewed [256,257] 10 genes in mammals share both a
PDZ domain and one or more LIM domains and have been subdivided
based on their structure and phylogenetic similarities: 4 genes of the
ALP subfamily (ALP, CLIM1/CLP36, Mystique and RIL), 3 genes of the
Enigma subfamily (Enigma, EnigmaHomolog and ZASP/Cypher/Oracle),
2 genes of LIM kinases (LIMK1 and LIMK2) and the LIM only 7 (LMO7)
gene. LIMK1, LIMK2 and LMO7 have been found in the developing and
adult heart, and although in non-muscle cells they are involved in
microtubule stability and F-actin polymerization, and possibly cell–cell
junction integrity, their roles remain to bedetermined in the heart [256].
4.4.3.4. ALP (α-actinin associated LIM protein). Four protein members
have been classiﬁed as belonging to the ALP (α-actinin associated LIM
protein) subfamily and each consist of an N-terminal PDZ domain anda C-terminal LIM domain. All interact with α-actinin however solely
ALP and CLP36 are known to be present in the heart [257]. While
CLP36 (in rats) and the human homologue CLIM1 are highly abundant
in heart muscle [258,259], their function remains to be determined.
ALP was the ﬁrst member of this subfamily to be described and it
was shown to bind and co-localize with α-actinin at the Z-disc via its
PDZ domain [260]. In striated muscle, ALP is expressed in high levels
in skeletal muscle and low levels in the heart [260], although it pre-
dominates in the right ventricle [261]. ALP-deﬁcient mice present
right ventricular chamber dilation and dysfunction, which led the
authors to suggest that ALP is essential for the embryonic develop-
ment of the right ventricle of mice possibly assisting the embryo to
high biomechanical load [261]. In accordance, ALP would enhance
the ability of α-actinin to cross-link actin ﬁlaments, thus ensuring a
greater mechanical protection [261]. In addition, over-expression of
ALP in a transgenic mouse model revealed that ALP colocalized with
α-actinin and β-catenin at the intercalated disc [261]. Interestingly,
β-catenin is also able to bind to α-actinin [262], indicative for an
ALP-α-actinin–β-catenin multiprotein complex. β-catenin accumula-
tion at the intercalated discs is associated with cell–cell junction
disruption and development of hypertrophy [263]. ALP-deﬁcient not
solely present right ventricular chamber dilation [261], but also ex-
hibit a compromise ability to trigger hypertrophic growth [264]. It is
possible that the inability to bind to α-actinin disrupts the formation
of a stable complex of ALP-α-actinin–β-catenin, resulting in a defective
physical connection with the actin cytoskeleton.
4.4.3.5. Enigma, enigma homolog and ZASP/Cypher/Oracle. Enigma con-
sists of the typical N-terminal PDZ domain and 3 C-terminal LIM
domains [265]. Enigma has been shown to bind to actin [266] and
together with APS (adaptor protein with PH and SH2 domains) has
been shown to bind F-actin and regulate actin-cytoskeleton reorgani-
zation in non-muscle cells [267]. In the sarcomere, Enigma is found
anchored to the Z-disc (~80%), with the rest localized in the I- and
A-bands [268]. Interestingly via its PDZ domain, Enigma binds to the
C-terminal region of skeletal β-tropomyosin at the boundary of the
I-band and Z-disc, indicative for a regulatory role in cardiac thin ﬁla-
ment assembly at the Z-disc [268]. Despite the interesting putative
functions of Enigma association to cytoskeleton assembly and trans-
duction of signals, at present the role of Enigma in the heart remains
to be determined.
Enigma Homolog protein (ENH) was ﬁrst identiﬁed after a yeast
two-hybrid screening of putative interacting proteins with protein ki-
nase C (PKC) [269]. Via its PDZ domain ENH interacts with α-actinin
at the Z-disc of cardiac and skeletal tissue [270,271]. In addition, it has
been shown that ENH interacts with protein kinase D (PKD) and
L-type Ca2+-channels in rat cardiomyocytes [272]. In humans, four
ENH isoforms have been identiﬁed, of which ENH1 is ubiquitously
expressed and the other three isoforms are limited to the adult
heart [269,271]. Yamazaki and colleagues [273] showed that ENH1
is highly expressed in the embryonic and neonatal rat hearts, while
it is down-regulated and replaced by ENH3 and ENH4 in the adult
heart. Over-expression of ENH1 in neonatal cardiomyocytes was as-
sociated with expression of hypertrophic markers, while ENH4 over-
expression prevented those alterations. Of particular interest, hyper-
trophy induced by aortic constriction resulted in ENH1 upregulation,
in contrast to down-regulation of ENH4 [273]. As recently proposed
[274] ENH1 up-regulation following mechanical stretch may anchor
PKC and/or PKD via its LIM domains, since ENH3 and/or ENH4 are un-
able to interact and activate these kinases (they lack LIM domains).
In turn, PKC-induced phosphorylation would initiate transcription
of hypertrophic growth genes [274]. Transgenic mice lacking ENH
develop DCM following mechanical overload, which supports the
role of ENH as potential mediator of hypertrophic responses [275].
ZASP [162]/Cypher [164]/Oracle [276] was independently identiﬁed
by three different groups and was found to detain an important role in
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spliced PDZ motif protein) is the human ortholog member and was
shown to localize at the Z-disc, where it interacts through its PDZ
domain with α-actinin [162,164] and nebulette [205]. Cypher also
interacts with myotilin and FATZ-2, although the role of these alter-
ations remains unclear [184]. Cypher-null mice have early postnatal
death with disorganized Z-discs and DCM development [184,277]. It
has been suggested that Cypher is not required for striated muscle
development or Z-disc embryonic assembly, but instead is required
for adult Z-disc maintenance during muscle contraction [184,277].
Mutations in the ZASP gene have been identiﬁed in patients with
DCM [91,278] and HCM [279]. In addition, zaspopathy-causing
MFM have also been found and are characterized by late onset with
muscle weakness [280].
ZASP/Cypher also interacts with PKC via its LIM-domains, which
suggests that it couples PKC-mediated signaling to the cytoskeleton
[164]. Of particular interest, PKCε over-expression enhances its
co-localization with membrane proteins, such as RACK (receptors
for activated C kinase), resulting in cardiac hypertrophy, while inhi-
bition of this interaction is observed in DCM [281–283].
Altogether these studies support the notion that these proteins
serve dual roles in the myoﬁlaments as both cytoskeleton adaptor
proteins and signaling proteins. In agreement, via their LIM domains
they recruit signaling proteins, such as PKC, and via their PDZ domain
interact with cytoskeletal proteins including α-actinin, tropomyosin
and nebulette.
4.4.3.6. LIM-only proteins. LIM-only proteins are Z-disc associated
proteins that consist of LIM domains and are involved in cytoskeletal
organization and integrity. In the present review, we will focus
on two of these members: zyxin [284] and muscle LIM protein
(MLP) [285].
Zyxin is suggested to be both involved in cytoskeleton organization,
where it anchors to the Z-disc by interacting with α-actinin [166],
nebulette [203], MLP [286] and myopodin [287], and is involved in
intracellular signaling between the nucleus and the costamere
[288,289]. cGMP-dependent nuclear translocation of zyxin after ANP
(atrial natriuretic peptide) receptor stimulation of cardiomyocytes,
results in zyxin–Akt interaction and potentiates cell survival, indicative
of its anti-apoptotic effects [290]. Activation of cGMP/PKG (protein
kinase G) has proven essential in survival signaling during ischemia–
reperfusion [291], which is possibly partly associated with the role of
zyxin-induced survival of cardiomyocytes.
MLP is speciﬁcally expressed in striated muscle and it is
suggested to be involved in myogenesis and stretch signaling
responses [92,285,292]. Several binding partners have been
demonstrated to interact with MLP including α-actinin and N-RAP
[293], zyxin [286], telethonin [294], ILK [295], calcineurin [296],
myoD [297] and β-spectrin [298]. The precise location and function
of MLP remains however controversial. It has been reported that
MLP is either ﬂanking [92] or located at the Z-disc (bound to
telethonin, see below), suggesting that MLP is a cardiac-stretch
sensor [294]. MLP-causing mutations associated with HCM result
in decrease MLP binding to both N-RAP and α-actinin [293],
which may argue for Z-disc location during early steps of myoﬁbril
assembly. In addition, MLP-null mice develop severe DCM with major
defects in cytoskeletal organization [92], associated with decreased
passive tension compared to wild-type mice [294] and increase N-RAP
expression [299], possibly to maintain normal myoﬁbril assembly.
On the other hand, other laboratories however failed to detect
MLP at the Z-disc in both neonatal and adult cardiac tissue. Recent
evidence indicates that MLP rather has a subcellular localization
including the nucleus, the costamere and the cytosol, making it less
likely that MLP works as a direct sarcomeric-stress sensor
[292,298,300,301]. Instead, MLP may act as a signaling transducer in
mechano-sensory cascades [292,302]. In failing human hearts, due toischemic cardiomyopathy and DCM, MLP expression was reduced
[303]. Mutations in the MLP gene have been linked to either HCM
[301] or DCM [156], which highlights the complexity ofMLP-derived ef-
fects in disease progression.
In summary, the Z-disc comprises the lateral boundaries of the
sarcomere, responsible for the anchorage of the thin ﬁlament andmain-
tains the stable propagation of force during contraction. Traditionally it
is believed that the generated forces of cross-bridges within each sarco-
mere are transmitted longitudinally to the adjacent sarcomere along
the myoﬁbril, although evidence suggests it may only account to ~20–
30% of total force transmited [215]. This indicates that the major prop-
agation of force follows a lateral pathway across the sarcolemma,
which possibly involves the costameres. The costameres make up
the lateral connections of the Z-disc with the sarcolemma and ECM,
thus providing a homogeneous transmission of force between
neighboring sarcomeres and ensure greater mechanical resis-
tance. The costameres are responsible for the physiological and
pathological adaptations of cardiomyocytes accompanying me-
chanical load. Dystrophin–glycoprotein and integrin–vinculin–
talin complexes are central to preserve sarcolemmal and ECM in-
tegrity via integration and transduction of biomechanical signals.
Abnormalities caused bymutations in these elements may restrict their
capacity to monitor stress, weakening attachment of the ECM to the
cytoskeleton, disrupting Z-disc alignment and transmission of force,
as observed in DCM and muscular dystrophies. Nonetheless, as shown
by full knock-out animal models of several of these components, the
Z-disc tries to compensate for the loss of some of its members. Trans-
duction of biomechanical signals is accomplished via anchorage at the
Z-disc of specialized cytoskeletal proteins (e.g. FATZ, ENH, ZASP and
zyxin) that monitor and sense mechanical stress. These are able to
recruit and interact with protein phosphatases and/or kinases, and
regulate cardiac remodeling. Altogether these ﬁndings support a very
dynamic Z-disc structure, capable of integrating and transducing bio-
mechanical signals, and adapt cardiomyocytes during physiological
and pathological conditions.4.5. The third ﬁlament: titin
4.5.1. Titin assembly
Involved in the development and organization of the sarcomere,
titin [304] (or connectin [305]) has been considered central in the
heart's adaptation to biomechanical stress. Titin is a giant protein with
a molecular weight ranging from 3.0 to 3.8 MDa that extends from the
Z-disc to theM-band [306,307]. In the Z-disc, the N-terminal ends over-
lap adjacent titin polypeptides and are capped by the cap protein
telethonin (also known as T-cap) [308,309]. Telethonin has been de-
tected in early myotube formation in differentiating myocytes where
it is phosphorylated by the titin-kinase [309,310]. Additionally, the
N-terminal insertion of titin in the Z-disc interacts with actin [311]
and possibly also α-actinin [312,313] via a 45 amino acid repeat region
(i.e. Z-repeats) suggested to provide a mechanism of Z-disc assembly of
variable thickness as a result of alternative splicing [314]. The I-band
region of titin is the extensible region and consists of three elastic com-
ponents that act as a spring element: 1) tandem immunoglobulin
(Ig)-like domain regions, with proximal (near Z-disc) and distal (near
I–A regions) segments, 2) the PEVK sequence-region rich in proline
(P), glutamic acid (E), valine (V) and lysine (K) and 3) the N2B and
N2BA elements (both isoforms contain N2B segments, but only the
N2BA isoform contains an additional N2A element) [315]. The A-band
region of C-terminal ends of titin is inextensible, as they interact
with thick ﬁlament and associated proteins, such as myosin and
cMyBP-C [307,316,317]. In the M-band, titin molecules from oppos-
ing half-sarcomeres intersect, where they are interconnected by
M-band proteins, thereby forming a continuous ﬁlament from the
M-band towards the Z-disc [318,319].
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Under resting conditions, striatedmuscle resistsmuscle lengthening
by producing passive tension in response to stretch. In the heart, titin
accounts for approximately 80% of total passive tension between phys-
iological operating sarcomere lengths (i.e. 1.8 to 2.2 μm). Interestingly,
over-stretching cardiacmuscle above 2.2 μm,where the contribution of
collagen is greater, the titin stretch-based passive tension remains high,
indicative of the central role of titin to respond to stretch [132,133].
Passive (resting) tension results from the extensible I-band spring seg-
ment of titin that elongates as sarcomere length increases. The tandem
Ig-like segments are the ﬁrst to extend, followed by the PEVK segment
and lastly, the elongation of the N2B segement [318,319]. The ﬂexibility
and stretch-based passive tension of the titin spring elements can be
regulated by two major mechanisms: a fast “acute” modulation by
1) post-translational modiﬁcations via protein phosphorylation and a
2) “chronic” isoform shift due to alternative splicing of the I-band
encoding region of the titin (TTN) gene gives rise to different isoforms.
Titin-dependent phosphorylation by protein kinases has been dem-
onstrated to regulate cardiomyocyte stiffness. In accordance, PKA and
PKGphosphorylate titin at theN2B unique sequence (N2Bus) and result
in decreased cardiomyocytes stiffness [20,320–322], whereas PKCα
phosphorylates titin at the PEVK region which increases stiffness
[323,324]. In cardiomyocytes from HFpEF patients high stiffness has
been detected, which was corrected upon PKA administration [325].
The high passive stiffness in HFpEF was related to a titin phosphoryla-
tion deﬁcit [31]. More recently, reduced cGMP/PKG activity has been
found in HFpEF patients and a large HFpEF animal model [326–328].
Exogenous administration of PKG was able to lower the high titin-
based stiffness [326–328]. In addition both the N2Bus and PEVK can
bephosphorylated by CaMKIIδ, whichhas been associatedwith a reduc-
tion in passive stiffness [329,330]. Both activity and expression of
CaMKII were found to be higher in end-stage failing human hearts
than in non-failing donors [330].
In addition to post-translational modiﬁcations of titin, alternative
splicing [331]. The small isoform (~3.0 MDa) of titin is termed N2B
and contains a unique sequence (N2Bus) characteristic of cardiac
titin [331]. In addition to N2B, the I-band region of titin also contains
the N2A element, producing a larger titin termed N2BA, resulting in a
longer PEVK segment and additional Ig-like domain regions (~3.3–
3.5 MDa), turning it into a more compliant titin [318,331]. During
heart development and neonatal stages, the isoforms contain additional
spring elements in both tandem Ig-like domain regions and PEVK re-
gions, which result in an even greater titin isoform (~3.6–3.8 MDa)
[318,332]. In the adult human heart, both N2B and N2BA isoforms are
expressed, although the population of the smaller N2B spring element
predominates. To this extent, the isoform content ratio (N2BA:N2B)
determines the amount of passive tension, such that the smaller this
ratio, the greater cardiac stiffness is generated [333–335]. An increased
N2BA:N2B ratio is observed in DCM patients resulting in reduced
cardiomyocyte stiffness [334,336]. Together, these studies support the
central role of titin-isoform shift and phosphorylation in modulation
of cardiomyocytes stiffness in HF patients.
4.5.3. Titin, a regulator of length-dependent activation
Titin is not just solely a passive spring element, as emerging evi-
dence indicates it may also play a role in the development of active
tension and serve as a length-dependent sensor. In accordance, a cor-
relation between enhanced length-dependent activation and higher
levels of passive tension has been reported [337–339]. It is suggested
that titin-based passive tension potentiates cross-bridge formation
via reduction of lattice spacing upon stretch [338,339]. A recent
study supports this idea, as reduced myoﬁlament force development
and cycling rates, and impaired length-dependent activation [340]
were found in a rat that harbors a homozygous autosomal mutation
that expresses a giant titin isoform (N2BA-G, ~3.9 MDa) [341]. Alto-
gether, these ﬁndings indicate that titin affects the contractileapparatus by affecting cross-bridge cycling kinetics, possibly regu-
lating myoﬁlament length-dependent activation.
4.5.4. Titin, an integrator of the mechano-sensory machinery
Titin alsomediates mechano-sensory events in response to stress.
A variety of titin binding-partners have been reported to adapt to
sustained pressure-overload and activate hypertrophic signaling
responses. It is beyond the scope of this review to detail a thorough
discussion of these pathways and therefore, we refer the reader to
extensive reviews on the topic (see Refs. [318,319,342]).
Accordingly, putative mechano-sensory pathways involving titin
include telethonin and several telethonin-interacting partners. It has
been demonstrated that telethonin binds at the Z-disc and recruits
MLP [294]. Resting non-stimulated cardiomyocytes present cytosolic
accumulation of MLP, which are translocated to the nucleus after hy-
pertrophic stimulation [343]. In addition, MLP elevation is observed
after myocardial infarction, indicative of its putative role during
cardiac remodeling [344]. MLP also binds to calcineurin [296] and
over-expression of calcineurin triggers cardiac hypertrophy, while
its inhibition suppresses development of hypertrophy [345]. Of par-
ticular interest, telethonin-deﬁcient mice have normal heart develop-
ment and function [346], but show progressive loss of t-tubules
and dys-synchronous Ca2+-transients that worsens with age [347].
Following pressure-overload increments, telethonin-deﬁcient mice
develop HF which was partly associated with cardiomyocyte death
by apoptosis [346] and further loss of t-tubules [347]. In accordance,
Knöll and colleagues [346] observed that telethonin and p53 (tumor
suppressor protein) co-localize in the nucleus following biomechani-
cal stress, resulting in p53's transcription repression. Mice lacking
telethonin are not able to repress p53 function and thus, have an in-
creased p53 expression and elevated apoptosis following pressure-
overload with progression to HF [346]. Together, these ﬁndings sup-
port that telethonin and its telethonin-interacting partners, may be
involved in the mediation of cardiac remodeling and hypertrophy
growth responses, in addition to maintain normal Ca2+-transients
associated with normal t-tubule structure. Additional support for
this view can be drawn from telethonin-causing mutations. Telethonin-
mutations can either cause HCM or DCM, which has been associated
with either increased interaction of telethonin with titin and FATZ-2, or
decreased binding of telethonin withMLP, titin and FATZ-2, respectively
[348]. One can speculate from these results that increased binding of
telethonin with its interacting-partners would potentiate the hypertro-
phic growth response, in contrast to its decrease binding associated
with a deﬁcit to trigger the hypertrophic signaling and development of
a dilated phenotype.
In addition, a link has been described between titin and members
of the four-and-a-half LIM domains (FHL) family at the I-band and
M-band, possibly involved in biomechanical stretch responses
[349,350]. Sheikh and colleagues [350] demonstrated that FHL1 inter-
acts with members of the mitogen-activated protein kinases (MAPK)
cascade (i.e. Raf1, MEK1/2 and ERK2) that are localized with the N2B
element of titin. Interestingly, FHL1 deﬁcient mice have a blunted
hypertrophic response with preserved cardiac function [350]. In ac-
cordance, deletion of the PEVK segment is associated with reduced
N2BA:N2B ratio and up-regulation of FHL1/2, and development of
cardiac hypertrophy [351], in contrast to cardiac atrophy with de-
creased FHL2 expression resulting from deletion of the N2B element
[352]. Together, these studies indicate that FHL plays a essential role
in biomechanical stress signaling via the N2B element of titin, possi-
bly by negative regulation of MAPK/hypertrophic signaling cascades.
In agreement, it was shown in FHL1-deﬁcient mouse that the N2B
element is a target of ERK2 phosphorylation, which is believed to
increase muscle compliance by lowering titin-based cardiac stiffness
[353]. These ﬁndings suggest that FHL1 and ERK2 are part of a
stretch-sensor complex in combination with the N2B element of
titin, in which they possibly exert dual roles following biomechanical
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of cardiac hypertrophy and 2) mask phosphorylation sites on the
N2B element, such as ERK-mediated phosphorylation, maintaining
baseline cardiac stiffness [353].
4.6. The M-band
4.6.1. M-band proteins
Located in the center of the A-band, the M-band provides the
regular packing of the thick ﬁlaments and allows the uniform distri-
bution of tension along the ﬁlament lattice structure. It has been
suggested that the M-band prevents sarcomere displacement by
promoting symmetric shortening of both sarcomere halves during
each contraction cycle, maintaining the alignment of the A-band
[354,355]. In addition to the C-terminus of titin and myosin tails,
three protein family members have been identiﬁed at the M-band:
myomesin [356] (MYOM1; ubiquitously expressed in all striated
muscles), M-protein [357] (MYOM2; expressed in adult heart and
fast-twitch skeletal muscle) and myomesin 3 (MYOM3; expressed
in human adult heart [358] (but not in mouse) and skeletal muscle)
[359]. Both myomesin and M-protein are suggested to interact with
titin and myosin [360–362], and the newly identiﬁed myomesin 3
shares the predicted-binding regions with M-protein to bind both
myosin and titin [359]. Myomesin exherts an analogous role to
α-actinin, as it forms anti-parallel dimers that link the thick ﬁla-
ments [363]. Mutations in myomesin that result in abnormal dimer-
ization of the protein have been linked to HCM in humans [364],
indicative of its putative role in sarcomere stability. During embry-
onic development another myomesin isoform is expressed (almost
absent in the adult heart) via alternative splicing of the myomesin
gene (MYOM1), termed embryonic heart (EH)-myomesin, resulting
in the inclusion of 100 amino residues [354,355]. Accordingly, it
has been shown that the EH-segment may serve as a molecular
spring in the M-band, working in a similar way to the PEVK region
of titin, protecting and preventing against extreme stretching and rup-
ture [365]. Since EH-myomesin is primarly expressed during embryonic
development with reduced postnatal expression and M-protein is only
expressed after birth, it indicates that differential amounts of these
M-band proteins may adjust the mechanical requirements of the
M-band to different working load conditions. One can speculate that
during HF situations, where up-regulation of fetal proteins are ob-
served, the mechanical rigidity of the M-band would be varied by
shifting from stiffer proteins (M-protein) to fetal more compliant
isoforms (EH-myomesin). In agreement, a recent study using MLP-
deﬁcient animals and human DCM patients observed a marked
up-regulation of EH-myomesin (41-fold) compared to both controls
and HCM patients [358]. In the MLP-deﬁcient animals, M-protein is
down-regulated and expression of myomesin 3 is observed [358].
As already mentioned, increased N2BA:N2B ratio is observed in
DCM patients resulting in reduced cardiomyocyte stiffness and much
greater compliant titin isoforms [334,336]. Together, these ﬁndings
suggest a dual adaptation of the cytoskeleton (i.e. M-band and titin)
to adapt during DCM development and support the dynamic role
exerted by the M-band.
4.6.2. M-band proteins and associated binding-partners
Several binding-partners have been shown to localize at the
M-band, the most pronounced interaction being muscle-type creatine
kinase (MM-CK) with myomesin and M-protein [366]. CK catalyzes
the re-phosphorylation of ADP to ATP by using phosphocreatine as
a substrate, thereby preventing excessive accumulation of ADP and
replenishing the available ATP essential for cross-bridge cycling [367].
In addition, other metabolic enzymes have been demonstrated to local-
ize at theM-band, such as adenylate kinase (involved in the conversion
of ATP to cAMP) and phosphofruktokinase (responsible for the regula-
tion of glucose levels) via interaction with FHL-2 [349]. Altogetherthese studies indicate a hot-spot for metabolic enzymes co-localization
within the sarcomere. Since FHL-2 interacts with the M-band region of
titin [349] and CK with myomesin and M-protein, the M-band seems
to represent a target for enzymes involved in energy consumption of
cardiac muscle.
As mentioned above, FHL members are suggested to modulate
stretch responses via interaction with integrins [368], which suggests
that the M-band may be able to mediate mechanical stress responses.
Following mechanical stress a link has been proposed between the
titin-kinase domain (located in the M-band region of titin) and the
MURF pathway involved in myocardial hypertrophic signaling, such
that it could serve as a mechano-sensory complex to trigger cardiac
hypertrophy [319]. A novel M-band component, termed myomasp
(myosin-interacting M-band-associated stress-responsive protein)/
LRRC39, has been recently discovered and suggested to be involved
in mechano-stretch sensing [369]. Of particular interest, myomasp
interacts with myosin, and myomasp-null mice have a dramatically
reduced expression of MYH7 and, MYOM1 and MYOM2 genes with
up-regulation of BNP (a marker for hypertrophic signaling). Disturbed
M-band architecture associated with low force generation was ob-
served in myomasp-deleted engineered hearts, and animal models
with aortic constriction showedadramatic down-regulation ofmyomasp.
It suggests that myomasp is a negative regulator of stretch-sensitive
genes and a modulator of the molecular composition of the M-band
[369].Moreover, it has been shown that both titin andmyomesin interact
with obscurin (Z-disc titin is also known to interactwith obscurin),which
appears essential for M-band assembly [370]. Obscurin is a giant protein
expressed in striated muscle (Mw ~800 KDa) that is suggested to modu-
latemyoﬁbril and sarcoplasmic reticulum(SR) organization andassembly
[371–373]. In accordance, obscurin interacts with ankyrin-1 at the
M-band (involved in sarcolemma-cytoskeleton interactions) and es-
tablishes obscurin–SR interactions [371]. Additionally, it has been
demonstrated that ankyrins function as adaptors for the localization
of dystrophin and dystroglycans at the costameres [374]. Recent
work has demonstrated a reduced localization of dystrophin (but
not dystroglycans) associated with reduced exercise tolerance,
muscle strength and sarcolemma fragility in obscurin-null mice
[136]. Of particular interest, wild-type animals presented a predom-
inant localization of ankyrin-B at the M-band that was lost in
obscurin-deﬁcient mice, indicative for the putative role of obscurin
in recruiting ankyrin-B [136]. Ablation of obscurin impaired the nor-
mal assemblies of themicrotubule network to the sarcolemma. Based
on this observation the authors hypothesized that uponM-banddisrup-
tion, the microtubule network at the subsarcolemmal region collapses,
and thereby alters the localization of dystrophin at the Z-disc. This
study thus suggests that obscurin is essential for ankyrin-B dependent
localization of dystrophin to the sarcolemma. A representative picture
of these interactions (proposed by Randazzo and colleagues [136]) is
presented in Fig. 3. It deserves however to be mentioned that the
intermolecular interactions between obscurin, ankyrin-B, the micro-
tubules and dystrophin reported [136] have only been identiﬁed in
skeletal muscle, and thus the existence of such interactions remain
to be determined in cardiac muscle and potential associated cardiac
pathologies.
5. Discussion
Cardiomyocytes are efﬁcient biochemical machineries special-
ized in the rapid generation of force and movement, central to the
work generated by the heart. Thick myosin ﬁlaments, powered by
ATPase activity, interdigitate with thin actin ﬁlaments, resulting in
the repetitive cycle of continuous attachment, sliding and detach-
ment, known as the cross-bridge cycle. Central to this system is the
delicate balance of intracellular Ca2+ ions, mediated by amechanism
known as excitation–contraction coupling, that bind to cTnC and
promote the steric Ca2+-regulation of troponin–tropomyosinmovement
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HCM-causing mutations of thick and thin ﬁlament proteins account for
~98% of all cases and are associated with alterations in Ca2+-handling,
actin-sliding velocities and ATPase activity, emphasizing the essential
role of these proteins in the contractile activity of the heart.
Mechanical stability of the thin ﬁlament proteins is ensured by its
anchorage to multiple-cytoskeletal proteins found at the Z-disc,
which contact the lateral boundaries of the sarcomere and provide
the stable propagation of force during contraction. The cross-linker
α-actinin forms a dynamic web capable of integrating multiple protein
complexes, and strengthens and aligns the Z-disc. The costameres form
the lateral connections of the Z-disc with the sarcolemma and ECM,
thus ensuring greater mechanical resistance. Mediated by γ-ﬁlamin,
F-actin bundle networks interact with both dystrophin–glycoprotein
and integrin–vinculin–talin complexes at the sarcolemma, which
make up a continuation to the ECM. DCM-causing mutations and
muscular dystrophies are associated with weakened attachment of
the ECM to the cytoskeleton, disruption of Z-disc alignment and re-
duced propagation of force. Inability of the costameres to monitor
and sense stress, thus limit their capacity to modulate and activate
stress-signaling pathways. In accordance, DCM has been associated
with increases in both dystrophin–glycoprotein protein synthesis
[375] and vinculin, but also in tubulin and desmin [239]. The increased
expression of cytoskeletal proteins possibly reﬂects compensatory re-
sponses to preserve the impaired management of contractile stress.
Not solely important for the generation of active tension, cardiac
muscle is composed of spring elements like titin that importantly
align the A-band during cardiac relaxation and together with the sur-
rounding connective tissue (ECM) resist excessive stretching, which
is known to cause severe myocardial damage [376–378]. Titin is the
main passive stretch modulator within physiological limits. Acute-
responses via post-translational modiﬁcations of titin or long-term
switches of titin's isoforms modulate the ability of the spring ele-
ments of titin to respond to stretch and adapt both systolic and dia-
stolic function of HF patients. This dynamic function of titin and
Z-disc components in modulating signaling pathways emphasize
their role as stress sensors. Recent evidence suggests that the
M-band is also able respond to stretch, which indicates that all struc-
tures of a myoﬁbril are able to manage stress and quickly adapt their
function to altered physiological and pathological situations.References
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